1. Home
  2. PHAR vs JBSS Comparison

PHAR vs JBSS Comparison

Compare PHAR & JBSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • JBSS
  • Stock Information
  • Founded
  • PHAR 1988
  • JBSS 1959
  • Country
  • PHAR Netherlands
  • JBSS United States
  • Employees
  • PHAR N/A
  • JBSS N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • JBSS Specialty Foods
  • Sector
  • PHAR Health Care
  • JBSS Consumer Staples
  • Exchange
  • PHAR Nasdaq
  • JBSS Nasdaq
  • Market Cap
  • PHAR 718.1M
  • JBSS 794.3M
  • IPO Year
  • PHAR N/A
  • JBSS 1991
  • Fundamental
  • Price
  • PHAR $11.24
  • JBSS $61.52
  • Analyst Decision
  • PHAR Strong Buy
  • JBSS
  • Analyst Count
  • PHAR 3
  • JBSS 0
  • Target Price
  • PHAR $30.00
  • JBSS N/A
  • AVG Volume (30 Days)
  • PHAR 3.1K
  • JBSS 82.4K
  • Earning Date
  • PHAR 05-08-2025
  • JBSS 04-30-2025
  • Dividend Yield
  • PHAR N/A
  • JBSS 3.37%
  • EPS Growth
  • PHAR N/A
  • JBSS N/A
  • EPS
  • PHAR N/A
  • JBSS 4.72
  • Revenue
  • PHAR $320,708,000.00
  • JBSS $1,107,742,000.00
  • Revenue This Year
  • PHAR $13.31
  • JBSS N/A
  • Revenue Next Year
  • PHAR $7.68
  • JBSS N/A
  • P/E Ratio
  • PHAR N/A
  • JBSS $13.16
  • Revenue Growth
  • PHAR 24.13
  • JBSS 7.40
  • 52 Week Low
  • PHAR $6.65
  • JBSS $58.47
  • 52 Week High
  • PHAR $11.07
  • JBSS $105.63
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 69.87
  • JBSS 43.07
  • Support Level
  • PHAR $10.02
  • JBSS $61.17
  • Resistance Level
  • PHAR $10.89
  • JBSS $62.57
  • Average True Range (ATR)
  • PHAR 0.23
  • JBSS 1.61
  • MACD
  • PHAR 0.11
  • JBSS 0.27
  • Stochastic Oscillator
  • PHAR 100.00
  • JBSS 45.16

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About JBSS John B. Sanfilippo & Son Inc.

John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.

Share on Social Networks: